**Name of Journal:** *World Journal of Nephrology*

**Manuscript NO:** 66128

**Manuscript Type:** SYSTEMATIC REVIEWS

**Prediction of mortality among patients with chronic kidney disease: A systematic review**

Hansrivijit P *et al*. Prediction of mortality among CKD patients

Panupong Hansrivijit, Yi-Ju Chen, Kriti Lnu, Angkawipa Trongtorsak, Max M Puthenpura, Charat Thongprayoon, Tarun Bathini, Michael A Mao, Wisit Cheungpasitporn

**Panupong Hansrivijit, Yi-Ju Chen, Kriti Lnu,** Department of Internal Medicine, UPMC Pinnacle, Harrisburg, PA 17104, United States

**Angkawipa Trongtorsak,** Department of Internal Medicine, Amita Health Saint Francis Hospital, Evanston, IL 60202, United States

**Max M Puthenpura,** Department of Medicine, Drexel University College of Medicine, Philadelphia, PA 19129, United States

**Charat Thongprayoon, Wisit Cheungpasitporn,** Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, MN 55905, United States

**Tarun Bathini,** Department of Internal Medicine, University of Arizona, Tucson, AZ 85721, United States

**Michael A Mao,** Division of Nephrology and Hypertension, Mayo Clinic, Jacksonville, FL 32224, United States

**Author contributions:** Hansrivijit P contributed to acquisition of data, analysis, and interpretation of data, drafting the article, and final approval; Chen YJ, Lnu K and Trongtorsak A contributed to acquisition of data, analysis of data, and drafting the article; Puthenpura MM contributed to acquisition of data and drafting the article; Thongprayoon C and Bathini T contributed to acquisition of data and final approval; Mao MA and Cheungpasitporn W contributed to interpretation of data, revising the article, and final approval.

**Correspondence to: Wisit Cheungpasitporn, FACP, FASN, FAST, Associate Professor,** Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, 200 1st St SW, Rochester, MN 55905, United States. wcheungpasitporn@gmail.com

**Received:** March 21, 2021

**Revised:** May 11, 2021

**Accepted:** July 23, 2021

**Published online:**

**Abstract**

BACKGROUND

Chronic kidney disease (CKD) is a common medical condition that is increasing in prevalence. Existing published evidence has revealed through regression analyses that several clinical characteristics are associated with mortality in CKD patients. However, the predictive accuracies of these risk factors for mortality have not been clearly demonstrated.

AIM

To demonstrate the accuracy of mortality predictive factors in CKD patients by utilizing the area under the receiver operating characteristic (ROC) curve (AUC) analysis.

METHODS

We searched Ovid MEDLINE, EMBASE, and the Cochrane Library for eligible articles through January 2021. Studies were included based on the following criteria: (1) Study nature was observational or conference abstract; (2) Study populations involved patients with non-transplant CKD at any CKD stage severity; and (3) Predictive factors for mortality were presented with AUC analysis and its associated 95% confidence interval (CI). AUC of 0.70-0.79 is considered acceptable, 0.80-0.89 is considered excellent, and more than 0.90 is considered outstanding.

RESULTS

Of 1759 citations, a total of 18 studies (*n* = 14579) were included in this systematic review. Eight hundred thirty two patients had non-dialysis CKD, and 13747 patients had dialysis-dependent CKD (2160 patients on hemodialysis, 370 patients on peritoneal dialysis, and 11217 patients on non-differentiated dialysis modality). Of 24 mortality predictive factors, none were deemed outstanding for mortality prediction. A total of seven predictive factors [N-terminal pro-brain natriuretic peptide (NT-proBNP), BNP, soluble urokinase plasminogen activator receptor (suPAR), augmentation index, left atrial reservoir strain, C-reactive protein, and systolic pulmonary artery pressure] were identified as excellent. Seventeen predictive factors were in the acceptable range, which we classified into the following subgroups: predictors for the non-dialysis population, echocardiographic factors, comorbidities, and miscellaneous.

CONCLUSION

Several factors were found to predict mortality in CKD patients. Echocardiography is an important tool for mortality prognostication in CKD patients by evaluating left atrial reservoir strain, systolic pulmonary artery pressure, diastolic function, and left ventricular mass index.

**Key Words:** Chronic kidney disease; End stage kidney disease; End stage renal disease; Dialysis; Mortality; Death; Predictors

Hansrivijit P, Chen YJ, Lnu K, Trongtorsak A, Puthenpura MM, Thongprayoon C, Bathini T, Mao MA, Cheungpasitporn W. Prediction of mortality among patients with chronic kidney disease: A systematic review . *World J Nephrol* 2021; In press

**Core Tip:** Although the current evidence has shown that several clinical factors are associated with mortality in chronic kidney disease (CKD), the accuracy of mortality prediction has not been clearly demonstrated. Our systematic review of studies that reported prognostic mortality factors using area under the receiver operating characteristic curve analysis in CKD patients provides an accuracy measurement. A total of 18 studies were identified. Eight hundred thirty two patients had non-dialysis CKD, and 13747 patients had end-stage kidney disease. Of 24 predictive factors, none were considered outstanding for mortality prediction. A total of seven predictive factors were identified as excellent. Our review summarizes the current accuracy of prognostic factors for CKD mortality.

**INTRODUCTION**

Chronic kidney disease (CKD) is defined by the presence of kidney damage (such as hematuria or structural abnormalities), an estimated glomerular filtration rate (eGFR) of less than 60 mL/min per 1.73m2, or albuminuria of greater than 30 mg in 24 h with duration of more than 3 mo[1]. The prevalence of CKD ranges from 8% to 16% of the population worldwide[2,3]. CKD is more prevalent in low- and middle-income countries compared with high-income countries[4]. With the increasing prevalence of hypertension and diabetes, it is projected that CKD prevalence in adults over 30-years-old will increase from 14.4% in 2020 to 16.7% in 2030[5]. Moreover, in the general population of the United States, the average GFR decline rate is approximately 1 mL/min per 1.73m2 per year[6,7] with a lifetime risk of developing CKD (as defined by eGFR less than 60 mL/min per 1.73m2) of more than 50%[8].

Progression of CKD has been associated with significantly increased adverse clinical outcomes, such as end-stage kidney disease (ESKD), dialysis dependence, cardiovascular events, and all-cause mortality[9,10]. Tonelli *et al*[11] conducted a meta-analysis of 38 studies that included over 1.3 million participants. They showed that the absolute risk for death increased exponentially with decreasing kidney function[11]. Several risk factors have been identified to predict mortality in CKD patients. One meta-analysis demonstrated that age, diabetes, previous cardiovascular disease, adiponectin, and C-reactive protein are all risk factors for mortality in dialysis patients[12]. Alternatively, an analysis of the Cleveland Clinic CKD Registry of 621 CKD patients with age > 65 years showed that increasing age, congestive heart failure, absence of arteriovenous fistula, and lack of nephrology care prior to dialysis initiation were significant risk factors for increased 1-year mortality after dialysis initiation[13]. However, data on mortality risk factors for non-dialysis dependent CKD patients are limited.

Nearly all of the available evidence has reported their findings using regression analysis. Thus, the accuracy of mortality prediction has not been clearly demonstrated. In this study, we conducted a systematic review of studies that utilized associated area under the receiver operating characteristic (ROC) curve (AUC) analysis to report predictive factors for mortality in CKD patients. This method allows the reader to assess the predictive accuracy of distributional models in comparison with regression analyses[14]. Our findings would help guide the future design of an accurate mortality risk calculator for CKD patients.

**MATERIALS AND METHODS**

***Search strategy***

This manuscript follows the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-analysis)[15] statement as well as MOOSE (Meta-analysis of Observational Studies in Epidemiology)[16] guidelines. A systematic search was conducted through Ovid MEDLINE, EMBASE, and the Cochrane Library from each respective database inception to January 2021. The domain for the systematic search on Cochrane Library included PubMed, EMBASE, ClinicalTrials.gov, and International Clinical Trial Registry Platform (ICTRP). The following search terms were used: (“chronic kidney disease” OR “CKD” OR “end-stage kidney disease” OR “ESKD” OR “end-stage renal disease” OR “ESRD”) AND (“mortality” OR “death” OR “survival”) AND (“area under curve” OR “AUC”). The detailed search strategy for each database is summarized in Supplementary material, Appendix 1. No language restrictions were applied during the systematic search.

***Inclusion criteria***

The eligibility of each study was determined by the following inclusion criteria: (1) The study nature was observational or conference abstract; (2) Study populations involved patients with non-transplant CKD at any CKD stage severity; and (3) Predictive factors for mortality were presented with AUC analysis and its associated 95% confidence interval (CI). Case reports, case series, review articles, or articles concerning pediatric patients were excluded. Study eligibility was independently evaluated by two investigators (Hansrivijit P and Chen YJ). Disagreements were resolved by mutual consensus among all authors. The quality of each study was appraised using the Newcastle-Ottawa quality scale which assesses six components: (1) representativeness of the subjects, (2) ascertainment of the exposure, (3) demonstration of the outcome of interest was not present at the start of study, (4) assessment of outcome, (5) follow-up duration period was long enough for the outcome to occur, and (6) adequate follow-up duration.

***Review process and data extraction***

The titles and abstracts of all references were screened (Hansrivijit P and Chen YJ) prior to proceeding with full-text review. The full-text of the selected screened articles were then reviewed to determine their eligibility for inclusion into the systematic review. A standardized data collection form was invented to extract the following information from included study: first author’s name, year of publication, country of origin, study design, subject(s), sample size, age, male sex, AUC and its 95%CI, and follow-up duration. Full articles or conference abstracts that reported the AUC without 95%CI were excluded. An AUC of 1.0 represents the ideal predictor with a 100% sensitivity and 0% false positive rate. Thus, in this mortality model, factors with AUC closer to 1.0 represented a better predictor for mortality, with AUC of 0.70-0.79 considered acceptable, 0.80-0.89 considered excellent, and more than 0.90 considered outstanding[17,18].

**RESULTS**

***Study characteristics***

A total of 1759 citations underwent three passes of article screening. After duplicates were removed, another 1665 irrelevant articles were excluded after the title and abstract were screened. The methods and results of the remaining 94 articles were then evaluated for eligibility in accordance with the inclusion criteria. Only 31 articles passed this stage to undergo full-text review. A final total of 18 studies from 2004 to 2021 consisting of 14579 subjects were included in this systematic review. Figure 1 provides a flowchart of the literature search and study selection. All studies were observational in nature (retrospective in 33.3% and prospective in 66.7%). The median age was 62.0 (± 4.1) years, and 57.3% were male. The median duration of follow-up was 2.0 (± 1.1) years. Table 1 describes the included study characteristics and results. The risk of bias assessment is shown in Supplementary Table 1.

***Study population***

Of 14579 patients from 18 studies, 832 patients had non-dialysis CKD, and 13,747 patients had dialysis-dependent CKD. Among studies that included dialysis-dependent CKD patients, 2160 patients required hemodialysis (HD) and 370 patients required peritoneal dialysis (PD). The remaining 11217 patients (from four studies) had been composed of a non-differentiated mixed population of HD and PD patients. Figure 2 illustrates the study population classification.

***Predictive factors for mortality***

A total of 24 predictive factors for mortality were identified. We classified these factors into three categories depending on their AUCs. None had an AUC greater than 0.90, which is considered outstanding for mortality prediction. The majority (*n* = 17) were in the acceptable range (AUCs 0.70-0.79). A total of seven predictive factors were identified as excellent (AUCs 0.80-0.89). Table 2 shows the predictive factors for mortality based on the population studied.

**DISCUSSION**

***Excellent predictors (AUC 0.80-0.89)***

N-terminal pro-brain natriuretic peptide (NT-proBNP) and brain natriuretic peptide (BNP) were found to be excellent predictors of mortality in dialysis patients[22,24]. In the general population, numerous factors such as age, female sex, and obesity can influence NT-proBNP level separate from heart failure[37]. BNP is eliminated by three main mechanisms: enzymatic metabolism, clearance through receptors, and urinary excretion[22]. Both BNP and NT-proBNP can be elevated in dialysis patients due to poor renal clearance, concomitant heart disease, heart failure, and volume expansion[38,39]. The mechanisms underlying the link between elevated BNP and NT-proBNP with increased mortality have not been fully established. One study suggested that chronic HD induces recurrent transient episodes of myocardial ischemia that result in myocardial stunning, hibernation, and remodeling[40]. Burton *et al*[40] described in this study that the decline in cardiac function and cardiac stunning were correlated with increasing BNP levels. These myocardial changes likely have a causative pathophysiologic role in the high cardiovascular complication rates and deaths in HD patients.

Soluble urokinase plasminogen activator receptor (suPAR) and C-reactive protein (CRP) were also excellent predictors for mortality in dialysis patients[29,36]. SuPAR is a proteolytic cleavage product of the glycosyl-phosphatidylinositol anchor of the urokinase plasminogen activator receptor expressed on immune and endothelial cells[41]. The concentration of suPAR is low in healthy individuals, but it becomes elevated in the presence of infection or inflammatory diseases[41]. Observational studies of dialysis patients have shown that higher suPAR levels are detected in patients that have severe angiographic coronary artery disease[29,42] or after cardiovascular events, both of which are associated with significantly increased cardiovascular death[43]. Increased suPAR levels are also associated with end-organ fibrosis, such as cirrhosis[44,45] and focal segmental glomerulosclerosis[46]. Similarly, CRP is a nonspecific acute phase reactant that can be elevated in the setting of infection or inflammatory processes[47]. Higher CRP levels are associated with pulmonary hypertension, which could represent crosstalk between inflammatory cells and pulmonary wall components[36,48,49]. Moreover, a population-based study demonstrated that CRP is independently associated with elevated parathyroid hormone levels (PTH) and increased mortality[50]. Elevated PTH in CKD patients can lead to renal osteodystrophy and accelerated vascular calcification. The associations between suPAR, CRP, and increased death suggest that these markers show promise for use as standard CKD mortality predictors in the future.

Echocardiography has been shown as a useful tool in the assessment of mortality risk in CKD patients. Gan *et al*[35] have demonstrated that impaired left atrial reservoir strain (LASr) is the best predictor of adverse cardiovascular outcomes in CKD stage 3-4 patients. In this assessment, the left atrium is divided into a total of 12 segments: six segments each from the apical four- and two-chamber views. LASr is measured from the average peak systolic strain from the 12 segments[35]. Impaired LASr is defined as ≤ 23%, based on a previously reported lower limit of reference value[51]. A few hypotheses have been postulated to link impaired LASr and mortality in the CKD population. First, the left atrium may be more predictive for mortality because it is a thin-walled chamber and may exhibit earlier alterations before the left ventricle[51]. Second, alterations of LASr irrespective of left ventricular (LV) function have been noted in heart failure with preserved ejection fraction[52], further highlighting it as a more sensitive marker. The underlying mechanisms for reduced LASr are believed to be a consequence of atrial fibrosis, which could be accelerated in the setting of CKD due to the attendant high systemic inflammatory state[53,54]. These potential pathophysiologic mechanisms may explain the significance of reduced LASr as an early indicator for poor outcomes in non-dialysis CKD patients.

Rroji *et al*[36] added that systolic pulmonary artery pressure (PAP) is predictive for mortality in dialysis patients. Other studies have concordantly shown that pulmonary hypertension (PH) confers a significant mortality risk in dialysis patients[55,56]. The prevalence of PH increases with CKD severity[55], and several studies have proposed mechanisms for the association between PH and CKD for both non-dialysis and dialysis patients. Arteriovenous fistulas for dialysis access and exposure to bio-incompatible dialysis membranes are a few of these factors that could increase the risk for PH in CKD patients[48,57]. The latter causes neutrophil activation that subsequently migrates to the lungs, resulting in increased pulmonary inflammation and vascular resistance[57]. For non-dialysis CKD patients, CKD itself can pathophysiologically directly incite pulmonary circulatory dysfunction and remodeling through uremic toxins, systemic inflammation, altered vasoregulation and endothelial dysfunction[48]. Altogether, prompt detection of PH *via* measurement of the systolic PAP could result in earlier intervention in order to prevent excess mortality in CKD patients.

Augmentation index (AIx) was predictive of mortality in CKD patients[32]. AIx was derived from the arterial pulse wave analysis using a tonometry-based SphygmoCor device[32]. Augmentation pressure (AP) is defined as the maximum systolic pressure subtracted from the inflection point pressure (the merging of incident and the reflected wave). AIx is defined as AP divided by pulse pressure (PP), presented as a percentage. This index represents arterial stiffness, which could be a result of various pathophysiologic mechanisms. For example, fibrosis, disruption of elastin fibers, calcification, or diffusion of macromolecules within arterial walls are potential contributors[32]. Although AIx is useful in predicting mortality in CKD patients, given the invasive nature of this procedure, the clinical use of this parameter to monitor and prognosticate outcomes in the ambulatory setting is limited.

***Acceptable predictors (AUC 0.70-0.79)***

**Non-dialysis population:** Several predictive factors for mortality have been identified among non-dialysis CKD participants. Urine protein creatinine ratio (UPCR), eGFR, mortality risk score and malnutrition inflammation score (MIS) have been demonstrated to be predictive of mortality in this patient population[28,30,31]. It is thus not surprising that Wang *et al*[21] reported that UPCR and eGFR are predictive of mortality among CKD patients. The presence of proteinuria in CKD patients has been widely associated with an increased risk of CKD progression and death[58]. Similarly, eGFR decline represents progression of CKD severity, which independently confers a significantly increased mortality risk[59,60]. Renal interstitial fibrosis/scarring and tubular atrophy are consistent with GFR decline and degree of proteinuria[58]. Along with these changes, the tubular epithelial cells are stimulated to synthesize reactive oxygen species, which further attracts inflammatory cells and interstitial myofibroblasts, leading to more fibrosis and scarring[58]. These interstitial changes are associated with CKD progression, which could indirectly increase mortality[58]. Thus, early interventions aiming to prevent proteinuria and CKD progression are essential for reducing mortality in CKD patients.

In 2019, Danial *et al*[30] developed a mortality risk score for CKD patients. In this study, the authors investigated mortality from adverse drug reactions (ADRs) that specifically occurred in CKD patients. The mortality risk prediction model included the following variables: (1) History of heart disease; (2) Dyslipidemia; (3) Electrolyte imbalance; (4) Psychotic agents; (5) Creatine kinase; (6) Total number of medications; and (7) Conservative management (how the treatment was provided to subjects with ADR)[30]. The authors noted that these clinical factors are easily obtained in clinical practice, and this score allowed preemptive identification of CKD patients at risk of ADR-associated mortality. These patients may thus have a significant benefit with early clinical intervention and medication adjustment. However, this model has not been proven to be predictive of mortality outside the scope of ADR, and consequently, its applicability in general CKD patients may be limited.

MIS is another mortality risk predictor tool for both pre-dialysis and dialysis-dependent CKD patients. The MIS consists of ten elements obtained from the past medical history, physical examination, body mass index, and laboratory indices[61]. In 2001, Kalantar-Zadeh *et al*[61] demonstrated that the MIS correlated with morbidity and mortality in maintenance HD patients. Later, Jagadeswaran *et al*[31] applied MIS to a pre-dialysis Indian population and found that MIS had a 56.5% sensitivity and 81% specificity (AUC 0.709; 95%CI: 0.604-0.815) for mortality prediction during a 36-mo follow-up. The mortality risk increased by 13.7% for each additional point in the MIS. These studies demonstrate the importance of malnutrition prevention for both pre-dialysis and dialysis-dependent CKD patients.

**Echocardiographic factors:** The ratios of early inflow velocity/annular diastolic velocity (E/E’) through the mitral valve and the LV mass index are predictive of mortality in CKD patients, regardless of dialysis status[28,36]. Mitral E/E’ ratio may be a marker of LV diastolic dysfunction[62] or a predictor of pulmonary hypertension[36]. Diastolic dysfunction has been associated with increased mortality in various CKD and non-CKD patient populations[63-65]. Similarly, an increased LV mass index represents LV hypertrophy, a well-established predictor for heart failure and death in CKD patients[66]. The 2013 European Society of Hypertension/European Society of Cardiology guidelines recommend performing echocardiography to refine cardiovascular risk assessment in hypertensive patients[67]. However, there are no recommendations specifically for CKD patients, despite studies showing an increased prevalence of LV hypertrophy with advancing CKD[68]. Our study further adds to the available evidence supporting echocardiography for mortality risk stratification in CKD patients. It should be highlighted that a combination of echocardiographic findings should be utilized to predict mortality in CKD patients, rather than isolated findings. This concept is supported by Tripepi *et al*[69] where the measurement of LV mass index in isolation does not provide significant prognostic value for CKD patients.

Real-time myocardial contrast echocardiography (MCE) is a non-invasive tool for assessment of myocardial ischemia in HD patients[70]. During this procedure, intravenous contrast is utilized to assess myocardial perfusion adequacy, which is defined as homogenous enhancement in > 50% of myocardial wall thickness for each segment[25]. One study showed that MCE and coronary angiography resulted in equal accuracy for anticipating combined cardiovascular endpoints and death[25]. The authors concluded that MCE is a safe and uncomplicated test that can aid in the selection of candidates for coronary revascularization. However, this data was limited to only HD patients. The utility of MCE should be confirmed in large multi-center studies of non-dialysis CKD patients.

**Comorbidities:** Comorbidities may serve as significant predictors for mortality in dialysis patients. Miskulin *et al*[20] investigated the index of coexisting disease (ICED) as an accurate mortality predictor in dialysis patients. In this study, ICED had greater discriminatory ability than other instruments. ICED is comprised of 19 medical conditions and 11 physical impairments; these are classified into four and three severity levels, respectively[20]. Another unique feature of ICED is the assessment of physical limitations, which has been shown as a strong prognostic factor in dialysis patients[71].

The Rennes comorbidity score and modified Charlson Comorbidity Index (CCI) have also been demonstrated to be predictive for mortality among dialysis patients[33]. The Rennes comorbidity score consists of seven components: Age, albumin level, cardiac, respiratory, and hepatic diseases, active malignancy, and walking disability[33]. Similarly, the modified CCI consists of 16 matrices composed of a wide range of medical comorbidities found in the original CCI plus patient’s age[33]. Pladys *et al*[33] found that the original CCI (without including patient’s age) had a low ability to predict 1-year mortality. Surprisingly, the Rennes score resulted in a very impressive ability to predict 1-year mortality among dialysis patients despite its inclusion of only seven variables[33]. Altogether, we conclude that specific comorbidities are crucial in determining mortality risk among dialysis patients. Not unexpectantly, accuracy is improved by the consideration of several high-yield comorbidities rather than relying solely on one particular comorbidity.

**Miscellaneous:** Acute physiologic assessment and chronic health evaluation (APACHE) III is an acceptable predictor for hospital, and 30-d mortality among HD patients admitted to the intensive care unit (ICU)[19]. The APACHE III prognostic system was invented in 1991 and has been validated in several patient populations[72]. The APACHE III is calculated from clinical data obtained during the first 24 h of ICU admission. It consists of several components, including the primary reason for ICU admission, age, sex, race, preexisting comorbidities, and location prior to ICU admission[72]. Although several modifications have been made to the original APACHE score, only APACHE III has confirmed accuracy for mortality prediction in critically ill HD patients. Dara *et al*[19] compared the performance of APACHE III with the SOFA score. They found that APACHE III outperformed SOFA score for mortality prediction in critically ill HD patients. In our systematic review, this was the only study that focused on ICU patients.

The prognostic value of serological biomarkers, such as cardiac troponin T (cTnT) and NT-proBNP, for mortality in dialysis patients has been shown in observational studies[21,22]. As noted earlier, these biomarkers highlight the association between cardiac remodeling and death in dialysis patients. cTnT has been shown to predict mortality in PD patients independent of inflammation, residual renal function, and cardiac hypertrophy[21]. This was supported by the recent Netherland Cooperative Study on the Adequacy of Dialysis report, where the predictive power of cTnT for mortality is superior to other risk factors in a mixed population of HD and PD patients[73]. We suggest the use of cTnT for its prognostic value in at least PD patients due to its ease of testing.

Pre-dialysis neutrophil-lymphocyte ratio (NLR) is a novel and strong short-term predictor for all-cause mortality in HD patients[27]. NLR has been shown to have predictive utility in numerous disease states, including acute myocardial infarction and autoimmune disease[74,75]. NLR represents systemic inflammation, nutritional status, and atherosclerosis, which are all prevalent in CKD patients[76,77]. One single-center Japanese cohort revealed that NLR is superior to other generic biomarkers for 1-year survival among patients with ESKD due to diabetic nephropathy[27]. Although the usefulness of NLR has been widely studied in CKD patients, more data on its accuracy in diverse CKD patients are needed.

Skin autofluorescence (SAF) has been studied in healthy and uremic individuals[78-80]. SAF is predictive of microvascular disease progression, cardiovascular events, and nonspecific adverse clinical outcomes in diabetic and CKD patients regardless of dialysis status[79,81-84]. SAF is measured by illuminating approximately 1 cm2 of skin surface with a 300-420 nm light source. SAF is calculated as the ratio between the emission light and reflected excitation light, multiplied by 100[32]. It is speculated that SAF represents the accumulation of advanced glycation end-products that cause collagen and elastin cross-linking, which can translate into increased arterial stiffness[85-87]. In 2019, Mukai *et al*[32] found that SAF in CKD patients is predictive of adverse clinical outcomes, including death. This study supports the association between SAF, arterial stiffness, and increased mortality in CKD patients.

PP is the difference between systolic and diastolic blood pressure. Rroji *et al*[36] demonstrated that PP has a significant impact on dialysis patient survival. In their study, patients with pulmonary hypertension had significantly higher PP compared with patients without pulmonary hypertension. The underlying mechanism between increased PP and death in CKD is not fully understood. However, we postulate that increased PP, either from a reduction of diastolic blood pressure or increase of systolic pressure, could increase morbidity and mortality due to reduced coronary perfusion pressure, elevated systemic vascular resistance, or decreased vascular compliance[88]. However, the predictive value of PP in CKD patients needs to be demonstrated in a larger study.

Detrended fluctuation analysis (DFA) of heart rate dynamics is another prognostic marker for PD patients. In recent years, heart rate variability derived from beat-to-beat heart rate dynamic monitors has been used as a surrogate marker of autonomic modulation in an effort to predict patient outcomes[89-91]. DFA is a scaling analysis method to represent the correlation properties of a signal[92]. This form of analysis permits the detection of long-range correlation embedded in non-stationary time series[93]. To date, a few studies have demonstrated that DFA provides significant information on risk of cardiovascular events in heart failure and acute coronary syndrome patients[94,95]. In 2016, Chiang and colleagues showed that lower short-term DFA was predictive of total mortality in PD patients (median follow-up duration of 34 mo)[26]. They were the first study to measure and associate autonomic dysregulation with clinical outcomes in ESRD patients. Subsequent studies have shown consistent data obtained from the general population, where reduced DFA was associated with increased mortality *via* sudden cardiac death[96]. DFA shows potential promise in CKD patients since ESRD is associated with an overactive sympathetic nervous system[97]. This dysregulation results in an amplification of intracellular cyclic AMP (cAMP), which leads to an increase of the action potentials in the sinoatrial node[98]. These pathophysiological changes can be detected in the altered beat-to-beat variability[99]. However, DFA is a relatively new method of clinical analysis, and its application in other patient populations such as HD and non-dialysis CKD remains to be elucidated.

***Limitations***

Our study has several limitations that should be considered. First, the predictive factors reported in each study were not homogenous. They varied from each study due to study design and patient population. Because of this limitation, a meta-analysis, subgroup analysis, and test of homogeneity could not be performed. Second, all included studies were observational in nature, making them susceptible to selection bias. However, we minimized this bias by conducting the risk of bias assessment. Third, the pooled sample size for PD patients remained relatively small compared to non-dialysis CKD and HD patients. Generalization of our research findings to the PD population should be cautiously performed. Nonetheless, the findings from our research could be applied towards the design of future prospective studies with the goal of developing a prognostication scoring system for mortality in CKD patients. To date, the outstanding factors (defined by AUC ≥ 0.90) for mortality prediction in CKD patients have yet to be discovered.

**CONCLUSION**

Several factors were identified to provide accurate predictions of mortality in CKD patients. Echocardiography is an important tool for mortality prognostication in CKD patients by evaluating LASr, systolic PAP, mitral E/E’ ratio, and LV mass index. NT-proBNP, BNP, suPAR, CRP, and AIx are excellent factors in mortality prediction among CKD patients.

**ARTICLE HIGHLIGHTS**

***Research background***

Chronic kidney disease (CKD) is a common medical condition that is increasing in prevalence. Understanding the accuracy of mortality risk factors in CKD patients could mitigate death.

***Research motivation***

Evidence has shown that several clinical factors are associated with mortality in CKD patients using regression analyses. However, the accuracy of these mortality predictive factors has not been clearly demonstrated.

***Research objectives***

To establish the accuracy of mortality predictive factors among CKD patients by utilizing the area under the receiver operating characteristic curve (AUC) analysis.

***Research methods***

Ovid MEDLINE, EMBASE, and the Cochrane Library were searched for eligible articles through January 2021. Only studies that reported their mortality predictive factors with AUC and 95% confidence interval were included. These factors were classified as acceptable, excellent, or outstanding based on their AUC.

***Research results***

Of 1759 citations, a total of 18 studies (*n* = 14579) were included in the systematic review. Eight hundred thirty two patients had non-dialysis CKD, and 13747 patients had dialysis-dependent CKD (2160 hemodialysis, 370 peritoneal dialysis, and 11217 undifferentiated modalities of dialysis). Of 24 predictive factors, none were considered outstanding for mortality prediction. A total of seven predictive factors (N-terminal pro-brain natriuretic peptide, brain natriuretic peptide, soluble urokinase plasminogen activator receptor, augmentation index, left atrial reservoir strain, C-reactive protein, and systolic pulmonary artery pressure) were identified as excellent. Seventeen predictive factors were in the acceptable range, which we classified into the following subgroups: predictors for the non-dialysis population, echocardiographic factors, comorbidities, and miscellaneous.

***Research conclusions***

This study determined several mortality risk factors for CKD patients that were deemed acceptable or excellent. Echocardiography is an important tool for mortality prognostication in CKD patients.

***Research perspectives***

The results of this study provide a preliminary perspective on the importance of identifying better prognostic factors for mortality in CKD patients. There is a lack of predictive risk factors with an AUC greater than 0.90. Currently identified mortality risk factors can be combined to create a risk calculator for CKD patients, which could be subsequently validated in future research.

**REFERENCES**

1 Erratum: Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). *Kidney Int Suppl*. 2017;7:1-59. *Kidney Int Suppl (2011)* 2017; **7**: e1 [PMID: 30681074 DOI: 10.1016/j.kisu.2017.10.001]

2 **Coresh J**, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F, Levey AS. Prevalence of chronic kidney disease in the United States. *JAMA* 2007; **298**: 2038-2047 [PMID: 17986697 DOI: 10.1001/jama.298.17.2038]

3 **Jha V**, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, Saran R, Wang AY, Yang CW. Chronic kidney disease: global dimension and perspectives. *Lancet* 2013; **382**: 260-272 [PMID: 23727169 DOI: 10.1016/S0140-6736(13)60687-X]

4 **Mills KT**, Xu Y, Zhang W, Bundy JD, Chen CS, Kelly TN, Chen J, He J. A systematic analysis of worldwide population-based data on the global burden of chronic kidney disease in 2010. *Kidney Int* 2015; **88**: 950-957 [PMID: 26221752 DOI: 10.1038/ki.2015.230]

5 **Hoerger TJ**, Simpson SA, Yarnoff BO, Pavkov ME, Ríos Burrows N, Saydah SH, Williams DE, Zhuo X. The future burden of CKD in the United States: a simulation model for the CDC CKD Initiative. *Am J Kidney Dis* 2015; **65**: 403-411 [PMID: 25468386 DOI: 10.1053/j.ajkd.2014.09.023]

6 **Peralta CA**, Vittinghoff E, Bansal N, Jacobs D Jr, Muntner P, Kestenbaum B, Lewis C, Siscovick D, Kramer H, Shlipak M, Bibbins-Domingo K. Trajectories of kidney function decline in young black and white adults with preserved GFR: results from the Coronary Artery Risk Development in Young Adults (CARDIA) study. *Am J Kidney Dis* 2013; **62**: 261-266 [PMID: 23473985 DOI: 10.1053/j.ajkd.2013.01.012]

7 **Grams ME**, Rebholz CM, Chen Y, Rawlings AM, Estrella MM, Selvin E, Appel LJ, Tin A, Coresh J. Race, APOL1 Risk, and eGFR Decline in the General Population. *J Am Soc Nephrol* 2016; **27**: 2842-2850 [PMID: 26966015 DOI: 10.1681/ASN.2015070763]

8 **Grams ME**, Chow EK, Segev DL, Coresh J. Lifetime incidence of CKD stages 3-5 in the United States. *Am J Kidney Dis* 2013; **62**: 245-252 [PMID: 23566637 DOI: 10.1053/j.ajkd.2013.03.009]

9 **van der Velde M**, Matsushita K, Coresh J, Astor BC, Woodward M, Levey A, de Jong P, Gansevoort RT; Chronic Kidney Disease Prognosis Consortium, van der Velde M, Matsushita K, Coresh J, Astor BC, Woodward M, Levey AS, de Jong PE, Gansevoort RT, Levey A, El-Nahas M, Eckardt KU, Kasiske BL, Ninomiya T, Chalmers J, Macmahon S, Tonelli M, Hemmelgarn B, Sacks F, Curhan G, Collins AJ, Li S, Chen SC, Hawaii Cohort KP, Lee BJ, Ishani A, Neaton J, Svendsen K, Mann JF, Yusuf S, Teo KK, Gao P, Nelson RG, Knowler WC, Bilo HJ, Joosten H, Kleefstra N, Groenier KH, Auguste P, Veldhuis K, Wang Y, Camarata L, Thomas B, Manley T. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. *Kidney Int* 2011; **79**: 1341-1352 [PMID: 21307840 DOI: 10.1038/ki.2010.536]

10 **Matsushita K**, Coresh J, Sang Y, Chalmers J, Fox C, Guallar E, Jafar T, Jassal SK, Landman GW, Muntner P, Roderick P, Sairenchi T, Schöttker B, Shankar A, Shlipak M, Tonelli M, Townend J, van Zuilen A, Yamagishi K, Yamashita K, Gansevoort R, Sarnak M, Warnock DG, Woodward M, Ärnlöv J; CKD Prognosis Consortium. Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data. *Lancet Diabetes Endocrinol* 2015; **3**: 514-525 [PMID: 26028594 DOI: 10.1016/S2213-8587(15)00040-6]

11 **Tonelli M**, Wiebe N, Culleton B, House A, Rabbat C, Fok M, McAlister F, Garg AX. Chronic kidney disease and mortality risk: a systematic review. *J Am Soc Nephrol* 2006; **17**: 2034-2047 [PMID: 16738019 DOI: 10.1681/ASN.2005101085]

12 **Ma L**, Zhao S. Risk factors for mortality in patients undergoing hemodialysis: A systematic review and meta-analysis. *Int J Cardiol* 2017; **238**: 151-158 [PMID: 28341375 DOI: 10.1016/j.ijcard.2017.02.095]

13 **Saeed F**, Arrigain S, Schold JD, Nally JV Jr, Navaneethan SD. What are the Risk Factors for One-Year Mortality in Older Patients with Chronic Kidney Disease? An Analysis of the Cleveland Clinic CKD Registry. *Nephron* 2019; **141**: 98-104 [PMID: 30463082 DOI: 10.1159/000494298]

14 **Grund B**, Sabin C. Analysis of biomarker data: logs, odds ratios, and receiver operating characteristic curves. *Curr Opin HIV AIDS* 2010; **5**: 473-479 [PMID: 20978390 DOI: 10.1097/COH.0b013e32833ed742]

15 **Moher D**, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med* 2009; **6**: e1000097 [PMID: 19621072 DOI: 10.1371/journal.pmed.1000097]

16 **Stroup DF**, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. *JAMA* 2000; **283**: 2008-2012 [PMID: 10789670 DOI: 10.1001/jama.283.15.2008]

17 **Mandrekar JN**. Receiver operating characteristic curve in diagnostic test assessment. *J Thorac Oncol* 2010; **5**: 1315-1316 [PMID: 20736804 DOI: 10.1097/JTO.0b013e3181ec173d]

18 **Hosmer Jr DW**, Lemeshow S, Sturdivant RX. Applied Logistic Regression, Third Edition. John Wiley & Sons, 2013

19 **Dara SI**, Afessa B, Bajwa AA, Albright RC. Outcome of patients with end-stage renal disease admitted to the intensive care unit. *Mayo Clin Proc* 2004; **79**: 1385-1390 [PMID: 15544016 DOI: 10.4065/79.11.1385]

20 **Miskulin DC**, Martin AA, Brown R, Fink NE, Coresh J, Powe NR, Zager PG, Meyer KB, Levey AS; Medical Directors, Dialysis Clinic, Inc. Predicting 1 year mortality in an outpatient haemodialysis population: a comparison of comorbidity instruments. *Nephrol Dial Transplant* 2004; **19**: 413-420 [PMID: 14736967 DOI: 10.1093/ndt/gfg571]

21 **Wang AY**, Lam CW, Wang M, Chan IH, Goggins WB, Yu CM, Lui SF, Sanderson JE. Prognostic value of cardiac troponin T is independent of inflammation, residual renal function, and cardiac hypertrophy and dysfunction in peritoneal dialysis patients. *Clin Chem* 2007; **53**: 882-889 [PMID: 17395709 DOI: 10.1373/clinchem.2006.078378]

22 **Sun L**, Sun Y, Zhao X, Xu C, Chen D, Li L, Ma Y, Rong S, Mei C. Predictive role of BNP and NT-proBNP in hemodialysis patients. *Nephron Clin Pract* 2008; **110**: c178-c184 [PMID: 18957868 DOI: 10.1159/000167270]

23 **Selim G**, Stojceva-Taneva O, Gelev S, Stojcev N, Dzekova P, Trajcevska L, Asani A, Busletic I, Pavleska S, Sikole A. A multi-biomarker approach for the prediction of cardiovascular mortality in hemodyalisis patients. International Journal of Artificial Organs. Conference: 37th Annual European Society for Artificial Organs, ESAO Congress. Skopje Macedonia. 72/74 via Friuli, 20135 Milan, Italy: Wichtig editore, 2010

24 **Breidthardt T**, Kalbermatter S, Socrates T, Noveanu M, Klima T, Mebazaa A, Mueller C, Kiss D. Increasing B-type natriuretic peptide levels predict mortality in unselected haemodialysis patients. *Eur J Heart Fail* 2011; **13**: 860-867 [PMID: 21628312 DOI: 10.1093/eurjhf/hfr057]

25 **Tomaszuk-Kazberuk A**, Sobkowicz B, Malyszko J, Malyszko JS, Hirnle T, Dobrzycki S, Mysliwiec M, Musial WJ. Real-time myocardial contrast echocardiography as a useful tool to select candidates for coronary revascularization among patients with end-stage renal disease - a 3-year follow-up study. *Adv Med Sci* 2011; **56**: 207-214 [PMID: 22112432 DOI: 10.2478/v10039-011-0050-y]

26 **Chiang JY**, Huang JW, Lin LY, Chang CH, Chu FY, Lin YH, Wu CK, Lee JK, Hwang JJ, Lin JL, Chiang FT. Detrended Fluctuation Analysis of Heart Rate Dynamics Is an Important Prognostic Factor in Patients with End-Stage Renal Disease Receiving Peritoneal Dialysis. *PLoS One* 2016; **11**: e0147282 [PMID: 26828209 DOI: 10.1371/journal.pone.0147282]

27 **Sato H**, Takeuchi Y, Matsuda K, Kagaya S, Saito A, Fukami H, Ojima Y, Nagasawa T. Pre-Dialysis Neutrophil-Lymphocyte Ratio, a Novel and Strong Short-Term Predictor of All-Cause Mortality in Patients With Diabetic Nephropathy: Results From a Single-Center Study. *Ther Apher Dial* 2017; **21**: 370-377 [PMID: 28665535 DOI: 10.1111/1744-9987.12533]

28 **Wang AYM**, Wu HH, Cai Q, Wong HKS, Lu X. Kidney and cardiac parameters-which are more important in predicting circulatory congestion and mortality risk in CKD Insights from a 5-year prospective analysis. *J Am Soc Nephrol* 2018; **29**: 416-417

29 **Wlazeł RN**, Szadkowska I, Bartnicki P, Rośniak-Bąk K, Rysz J. Clinical and prognostic usefulness of soluble urokinase plasminogen activator receptor in hemodialysis patients. *Int Urol Nephrol* 2018; **50**: 339-345 [PMID: 29313168 DOI: 10.1007/s11255-017-1778-5]

30 **Danial M**, Hassali MA, Meng OL, Kin YC, Khan AH. Development of a mortality score to assess risk of adverse drug reactions among hospitalized patients with moderate to severe chronic kidney disease. *BMC Pharmacol Toxicol* 2019; **20**: 41 [PMID: 31287030 DOI: 10.1186/s40360-019-0318-6]

31 **Jagadeswaran D**, Indhumathi E, Hemamalini AJ, Sivakumar V, Soundararajan P, Jayakumar M. Inflammation and nutritional status assessment by malnutrition inflammation score and its outcome in pre-dialysis chronic kidney disease patients. *Clin Nutr* 2019; **38**: 341-347 [PMID: 29398341 DOI: 10.1016/j.clnu.2018.01.001]

32 **Mukai H**, Svedberg O, Lindholm B, Dai L, Heimbürger O, Barany P, Anderstam B, Stenvinkel P, Qureshi AR. Skin autofluorescence, arterial stiffness and Framingham risk score as predictors of clinical outcome in chronic kidney disease patients: a cohort study. *Nephrol Dial Transplant* 2019; **34**: 442-448 [PMID: 29378035 DOI: 10.1093/ndt/gfx371]

33 **Pladys A**, Vigneau C, Raffray M, Sautenet B, Gentile S, Couchoud C, Bayat S. Contribution of medico-administrative data to the development of a comorbidity score to predict mortality in End-Stage Renal Disease patients. *Sci Rep* 2020; **10**: 8582 [PMID: 32444698 DOI: 10.1038/s41598-020-65612-x]

34 **Shahidi S**, Amooshahi M, Shekl Abadi E, Shekl Abadi R, Faghih N, Feizi A. SAT-221 Association of blood cell count, iron indices and hemoglobin level with mortality in hemodialysis patients. *Kidney Int Rep* 2020; **5**: S94-S95 [DOI:10.1016/j.ekir.2020.02.236]

35 **Gan GCH**, Kadappu KK, Bhat A, Fernandez F, Gu KH, Cai L, Byth K, Eshoo S, Thomas L. Left Atrial Strain Is the Best Predictor of Adverse Cardiovascular Outcomes in Patients with Chronic Kidney Disease. *J Am Soc Echocardiogr* 2021; **34**: 166-175 [PMID: 33223356 DOI: 10.1016/j.echo.2020.09.015]

36 **Rroji M**, Cafka M, Seferi S, Seiti J, Barbullushi M, Goda A. The potential effect of cardiac function on pulmonary hypertension, other risk factors, and its impact on survival in dialysis patients. *Int Urol Nephrol* 2021; **53**: 343-351 [PMID: 33389501 DOI: 10.1007/s11255-020-02655-z]

37 **Costello-Boerrigter LC**, Boerrigter G, Redfield MM, Rodeheffer RJ, Urban LH, Mahoney DW, Jacobsen SJ, Heublein DM, Burnett JC Jr. Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction. *J Am Coll Cardiol* 2006; **47**: 345-353 [PMID: 16412859 DOI: 10.1016/j.jacc.2005.09.025]

38 **Goetze JP**, Jensen G, Møller S, Bendtsen F, Rehfeld JF, Henriksen JH. BNP and N-terminal proBNP are both extracted in the normal kidney. *Eur J Clin Invest* 2006; **36**: 8-15 [PMID: 16403004 DOI: 10.1111/j.1365-2362.2006.01594.x]

39 **Haller C**, Zehelein J, Remppis A, Müller-Bardorff M, Katus HA. Cardiac troponin T in patients with end-stage renal disease: absence of expression in truncal skeletal muscle. *Clin Chem* 1998; **44**: 930-938 [PMID: 9590364]

40 **Burton JO**, Jefferies HJ, Selby NM, McIntyre CW. Hemodialysis-induced cardiac injury: determinants and associated outcomes. *Clin J Am Soc Nephrol* 2009; **4**: 914-920 [PMID: 19357245 DOI: 10.2215/CJN.03900808]

41 **Thunø M**, Macho B, Eugen-Olsen J. suPAR: the molecular crystal ball. *Dis Markers* 2009; **27**: 157-172 [PMID: 19893210 DOI: 10.3233/DMA-2009-0657]

42 **Eapen DJ**, Manocha P, Ghasemzadeh N, Patel RS, Al Kassem H, Hammadah M, Veledar E, Le NA, Pielak T, Thorball CW, Velegraki A, Kremastinos DT, Lerakis S, Sperling L, Quyyumi AA. Soluble urokinase plasminogen activator receptor level is an independent predictor of the presence and severity of coronary artery disease and of future adverse events. *J Am Heart Assoc* 2014; **3**: e001118 [PMID: 25341887 DOI: 10.1161/JAHA.114.001118]

43 **Meijers B**, Poesen R, Claes K, Dietrich R, Bammens B, Sprangers B, Naesens M, Storr M, Kuypers D, Evenepoel P. Soluble urokinase receptor is a biomarker of cardiovascular disease in chronic kidney disease. *Kidney Int* 2015; **87**: 210-216 [PMID: 24897037 DOI: 10.1038/ki.2014.197]

44 **Koch A**, Voigt S, Kruschinski C, Sanson E, Dückers H, Horn A, Yagmur E, Zimmermann H, Trautwein C, Tacke F. Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients. *Crit Care* 2011; **15**: R63 [PMID: 21324198 DOI: 10.1186/cc10037]

45 **Berres ML**, Schlosser B, Berg T, Trautwein C, Wasmuth HE. Soluble urokinase plasminogen activator receptor is associated with progressive liver fibrosis in hepatitis C infection. *J Clin Gastroenterol* 2012; **46**: 334-338 [PMID: 21934527 DOI: 10.1097/MCG.0b013e31822da19d]

46 **Wei C**, El Hindi S, Li J, Fornoni A, Goes N, Sageshima J, Maiguel D, Karumanchi SA, Yap HK, Saleem M, Zhang Q, Nikolic B, Chaudhuri A, Daftarian P, Salido E, Torres A, Salifu M, Sarwal MM, Schaefer F, Morath C, Schwenger V, Zeier M, Gupta V, Roth D, Rastaldi MP, Burke G, Ruiz P, Reiser J. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. *Nat Med* 2011; **17**: 952-960 [PMID: 21804539 DOI: 10.1038/nm.2411]

47 **Black S**, Kushner I, Samols D. C-reactive Protein. *J Biol Chem* 2004; **279**: 48487-48490 [PMID: 15337754 DOI: 10.1074/jbc.R400025200]

48 **Kawar B**, Ellam T, Jackson C, Kiely DG. Pulmonary hypertension in renal disease: epidemiology, potential mechanisms and implications. *Am J Nephrol* 2013; **37**: 281-290 [PMID: 23548763 DOI: 10.1159/000348804]

49 **Huertas A**, Tu L, Humbert M, Guignabert C. Chronic inflammation within the vascular wall in pulmonary arterial hypertension: more than a spectator. *Cardiovasc Res* 2020; **116**: 885-893 [PMID: 31813986 DOI: 10.1093/cvr/cvz308]

50 **Cheng SP**, Liu CL, Liu TP, Hsu YC, Lee JJ. Association between parathyroid hormone levels and inflammatory markers among US adults. *Mediators Inflamm* 2014; **2014**: 709024 [PMID: 24782595 DOI: 10.1155/2014/709024]

51 **Morris DA**, Takeuchi M, Krisper M, Köhncke C, Bekfani T, Carstensen T, Hassfeld S, Dorenkamp M, Otani K, Takigiku K, Izumi C, Yuda S, Sakata K, Ohte N, Tanabe K, Osmanoglou E, Kühnle Y, Düngen HD, Nakatani S, Otsuji Y, Haverkamp W, Boldt LH. Normal values and clinical relevance of left atrial myocardial function analysed by speckle-tracking echocardiography: multicentre study. *Eur Heart J Cardiovasc Imaging* 2015; **16**: 364-372 [PMID: 25368210 DOI: 10.1093/ehjci/jeu219]

52 **von Roeder M**, Rommel KP, Kowallick JT, Blazek S, Besler C, Fengler K, Lotz J, Hasenfuß G, Lücke C, Gutberlet M, Schuler G, Schuster A, Lurz P. Influence of Left Atrial Function on Exercise Capacity and Left Ventricular Function in Patients With Heart Failure and Preserved Ejection Fraction. *Circ Cardiovasc Imaging* 2017; **10** [PMID: 28360259 DOI: 10.1161/circimaging.116.005467]

53 **Freed BH**, Shah SJ. Stepping Out of the Left Ventricle's Shadow: Time to Focus on the Left Atrium in Heart Failure With Preserved Ejection Fraction. *Circ Cardiovasc Imaging* 2017; **10** [PMID: 28360263 DOI: 10.1161/CIRCIMAGING.117.006267]

54 **Rao AK**, Djamali A, Korcarz CE, Aeschlimann SE, Wolff MR, Stein JH. Left atrial volume is associated with inflammation and atherosclerosis in patients with kidney disease. *Echocardiography* 2008; **25**: 264-269 [PMID: 18307439 DOI: 10.1111/j.1540-8175.2007.00589.x]

55 **Walther CP**, Nambi V, Hanania NA, Navaneethan SD. Diagnosis and Management of Pulmonary Hypertension in Patients With CKD. *Am J Kidney Dis* 2020; **75**: 935-945 [PMID: 32199709 DOI: 10.1053/j.ajkd.2019.12.005]

56 **Tang M**, Batty JA, Lin C, Fan X, Chan KE, Kalim S. Pulmonary Hypertension, Mortality, and Cardiovascular Disease in CKD and ESRD Patients: A Systematic Review and Meta-analysis. *Am J Kidney Dis* 2018; **72**: 75-83 [PMID: 29429751 DOI: 10.1053/j.ajkd.2017.11.018]

57 **Bolignano D**, Rastelli S, Agarwal R, Fliser D, Massy Z, Ortiz A, Wiecek A, Martinez-Castelao A, Covic A, Goldsmith D, Suleymanlar G, Lindholm B, Parati G, Sicari R, Gargani L, Mallamaci F, London G, Zoccali C. Pulmonary hypertension in CKD. *Am J Kidney Dis* 2013; **61**: 612-622 [PMID: 23164943 DOI: 10.1053/j.ajkd.2012.07.029]

58 **Webster AC**, Nagler EV, Morton RL, Masson P. Chronic Kidney Disease. *Lancet* 2017; **389**: 1238-1252 [PMID: 27887750 DOI: 10.1016/S0140-6736(16)32064-5]

59 **Eriksen BO**, Ingebretsen OC. The progression of chronic kidney disease: a 10-year population-based study of the effects of gender and age. *Kidney Int* 2006; **69**: 375-382 [PMID: 16408129 DOI: 10.1038/sj.ki.5000058]

60 **Patel AD**, Ibrahim M, Swaminathan RV, Minhas IU, Kim LK, Venkatesh P, Feldman DN, Minutello RM, Bergman GW, Wong SC, Singh HS. Five-year mortality outcomes in patients with chronic kidney disease undergoing percutaneous coronary intervention. *Catheter Cardiovasc Interv* 2017; **89**: E124-E132 [PMID: 27519355 DOI: 10.1002/ccd.26664]

61 **Kalantar-Zadeh K**, Kopple JD, Block G, Humphreys MH. A malnutrition-inflammation score is correlated with morbidity and mortality in maintenance hemodialysis patients. *Am J Kidney Dis* 2001; **38**: 1251-1263 [PMID: 11728958 DOI: 10.1053/ajkd.2001.29222]

62 **Obokata M**, Reddy YNV, Borlaug BA. Diastolic Dysfunction and Heart Failure With Preserved Ejection Fraction: Understanding Mechanisms by Using Noninvasive Methods. *JACC Cardiovasc Imaging* 2020; **13**: 245-257 [PMID: 31202759 DOI: 10.1016/j.jcmg.2018.12.034]

63 **Tennøe AH**, Murbræch K, Andreassen JC, Fretheim H, Garen T, Gude E, Andreassen A, Aakhus S, Molberg Ø, Hoffmann-Vold AM. Left Ventricular Diastolic Dysfunction Predicts Mortality in Patients With Systemic Sclerosis. *J Am Coll Cardiol* 2018; **72**: 1804-1813 [PMID: 30286924 DOI: 10.1016/j.jacc.2018.07.068]

64 **Jentzer JC**, Anavekar NS, Mankad SV, Khasawneh M, White RD, Barsness GW, Rabinstein AA, Kashani KB, Pislaru SV. Echocardiographic left ventricular diastolic dysfunction predicts hospital mortality after out-of-hospital cardiac arrest. *J Crit Care* 2018; **47**: 114-120 [PMID: 29945067 DOI: 10.1016/j.jcrc.2018.06.016]

65 **Lassen MCH**, Sengeløv M, Qasim A, Jørgensen PG, Bruun NE, Olsen FJ, Fritz-Hansen T, Gislason G, Biering-Sørensen T. Ratio of Transmitral Early Filling Velocity to Early Diastolic Strain Rate Predicts All-Cause Mortality in Heart Failure with Reduced Ejection Fraction. *J Card Fail* 2019; **25**: 877-885 [PMID: 31336135 DOI: 10.1016/j.cardfail.2019.07.007]

66 **Dubin RF**, Deo R, Bansal N, Anderson AH, Yang P, Go AS, Keane M, Townsend R, Porter A, Budoff M, Malik S, He J, Rahman M, Wright J, Cappola T, Kallem R, Roy J, Sha D, Shlipak MG; CRIC Study Investigators. Associations of Conventional Echocardiographic Measures with Incident Heart Failure and Mortality: The Chronic Renal Insufficiency Cohort. *Clin J Am Soc Nephrol* 2017; **12**: 60-68 [PMID: 28062676 DOI: 10.2215/CJN.02700316]

67 **Mancia G**, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F; Task Force Members. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *J Hypertens* 2013; **31**: 1281-1357 [PMID: 23817082 DOI: 10.1097/01.hjh.0000431740.32696.cc]

68 **Park M**, Hsu CY, Li Y, Mishra RK, Keane M, Rosas SE, Dries D, Xie D, Chen J, He J, Anderson A, Go AS, Shlipak MG; Chronic Renal Insufficiency Cohort (CRIC) Study Group. Associations between kidney function and subclinical cardiac abnormalities in CKD. *J Am Soc Nephrol* 2012; **23**: 1725-1734 [PMID: 22935481 DOI: 10.1681/ASN.2012020145]

69 **Tripepi G**, D'Arrigo G, Mallamaci F, London G, Tangri N, Hsu JY, Feldman HI, Zoccali C. Prognostic values of left ventricular mass index in chronic kidney disease patients. *Nephrol Dial Transplant* 2021; **36**: 665-672 [PMID: 31860093 DOI: 10.1093/ndt/gfz254]

70 **Pérez de Isla L**, Rodrigo JL, Almería C, Pérez Ferro M, Serra V, Zamorano JL. Myocardial contrast echocardiography in coronary artery disease. *Eur J Echocardiogr* 2004; **5 Suppl 2**: S11-S16 [PMID: 15698555 DOI: 10.1016/s1525-2167(04)80003-9]

71 **McClellan WM**, Anson C, Birkeli K, Tuttle E. Functional status and quality of life: predictors of early mortality among patients entering treatment for end stage renal disease. *J Clin Epidemiol* 1991; **44**: 83-89 [PMID: 1986062 DOI: 10.1016/0895-4356(91)90204-m]

72 **Knaus WA**, Wagner DP, Draper EA, Zimmerman JE, Bergner M, Bastos PG, Sirio CA, Murphy DJ, Lotring T, Damiano A. The APACHE III prognostic system. Risk prediction of hospital mortality for critically ill hospitalized adults. *Chest* 1991; **100**: 1619-1636 [PMID: 1959406 DOI: 10.1378/chest.100.6.1619]

73 **Havekes B**, van Manen JG, Krediet RT, Boeschoten EW, Vandenbroucke JP, Dekker FW; NECOSAD Study Group. Serum troponin T concentration as a predictor of mortality in hemodialysis and peritoneal dialysis patients. *Am J Kidney Dis* 2006; **47**: 823-829 [PMID: 16632021 DOI: 10.1053/j.ajkd.2006.01.019]

74 **Ouellet G**, Malhotra R, Penne EL, Usvya L, Levin NW, Kotanko P. Neutrophil-lymphocyte ratio as a novel predictor of survival in chronic hemodialysis patients. *Clin Nephrol* 2016; **85**: 191-198 [PMID: 26951970 DOI: 10.5414/CN108745]

75 **Uslu AU**, Küçük A, Şahin A, Ugan Y, Yılmaz R, Güngör T, Bağcacı S, Küçükşen S. Two new inflammatory markers associated with Disease Activity Score-28 in patients with rheumatoid arthritis: neutrophil-lymphocyte ratio and platelet-lymphocyte ratio. *Int J Rheum Dis* 2015; **18**: 731-735 [PMID: 25900081 DOI: 10.1111/1756-185X.12582]

76 **Turkmen K**, Ozcicek F, Ozcicek A, Akbas EM, Erdur FM, Tonbul HZ. The relationship between neutrophil-to-lymphocyte ratio and vascular calcification in end-stage renal disease patients. *Hemodial Int* 2014; **18**: 47-53 [PMID: 23819627 DOI: 10.1111/hdi.12065]

77 **Agarwal R**, Light RP. Patterns and prognostic value of total and differential leukocyte count in chronic kidney disease. *Clin J Am Soc Nephrol* 2011; **6**: 1393-1399 [PMID: 21551023 DOI: 10.2215/CJN.10521110]

78 **Meerwaldt R**, Graaff R, Oomen PHN, Links TP, Jager JJ, Alderson NL, Thorpe SR, Baynes JW, Gans ROB, Smit AJ. Simple non-invasive assessment of advanced glycation endproduct accumulation. *Diabetologia* 2004; **47**: 1324-1330 [PMID: 15243705 DOI: 10.1007/s00125-004-1451-2]

79 **Meerwaldt R**, Hartog JW, Graaff R, Huisman RJ, Links TP, den Hollander NC, Thorpe SR, Baynes JW, Navis G, Gans RO, Smit AJ. Skin autofluorescence, a measure of cumulative metabolic stress and advanced glycation end products, predicts mortality in hemodialysis patients. *J Am Soc Nephrol* 2005; **16**: 3687-3693 [PMID: 16280473 DOI: 10.1681/ASN.2005020144]

80 **den Hollander NC**, Mulder DJ, Graaff R, Thorpe SR, Baynes JW, Smit GP, Smit AJ. Advanced glycation end products and the absence of premature atherosclerosis in glycogen storage disease Ia. *J Inherit Metab Dis* 2007; **30**: 916-923 [PMID: 17570077 DOI: 10.1007/s10545-007-0507-0]

81 **Lutgers HL**, Graaff R, Links TP, Ubink-Veltmaat LJ, Bilo HJ, Gans RO, Smit AJ. Skin autofluorescence as a noninvasive marker of vascular damage in patients with type 2 diabetes. *Diabetes Care* 2006; **29**: 2654-2659 [PMID: 17130200 DOI: 10.2337/dc05-2173]

82 **McIntyre NJ**, Fluck RJ, McIntyre CW, Taal MW. Skin autofluorescence and the association with renal and cardiovascular risk factors in chronic kidney disease stage 3. *Clin J Am Soc Nephrol* 2011; **6**: 2356-2363 [PMID: 21885790 DOI: 10.2215/CJN.02420311]

83 **Jiang J**, Chen P, Chen J, Yu X, Xie D, Mei C, Xiong F, Shi W, Zhou W, Liu X, Sun S, Zhang P, Yang X, Zhang Y, Zhang Y, Liang X, Zhang Z, Lin Q, Yu Y, Miyata T, Tian J, Liang M, Luo W, Xu X, Hou F. Accumulation of tissue advanced glycation end products correlated with glucose exposure dose and associated with cardiovascular morbidity in patients on peritoneal dialysis. *Atherosclerosis* 2012; **224**: 187-194 [PMID: 22857897 DOI: 10.1016/j.atherosclerosis.2012.06.022]

84 **Meerwaldt R**, Lutgers HL, Links TP, Graaff R, Baynes JW, Gans RO, Smit AJ. Skin autofluorescence is a strong predictor of cardiac mortality in diabetes. *Diabetes Care* 2007; **30**: 107-112 [PMID: 17192342 DOI: 10.2337/dc06-1391]

85 **Aronson D**. Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of aging and diabetes. *J Hypertens* 2003; **21**: 3-12 [PMID: 12544424 DOI: 10.1097/00004872-200301000-00002]

86 **Pischetsrieder M**. Chemistry of glucose and biochemical pathways of biological interest. *Perit Dial Int* 2000; **20** Suppl 2: S26-S30 [PMID: 10911639]

87 **Sims TJ**, Rasmussen LM, Oxlund H, Bailey AJ. The role of glycation cross-links in diabetic vascular stiffening. *Diabetologia* 1996; **39**: 946-951 [PMID: 8858217 DOI: 10.1007/BF00403914]

88 **Vidal-Petiot E**, Ford I, Greenlaw N, Ferrari R, Fox KM, Tardif JC, Tendera M, Tavazzi L, Bhatt DL, Steg PG; CLARIFY Investigators. Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study. *Lancet* 2016; **388**: 2142-2152 [PMID: 27590221 DOI: 10.1016/S0140-6736(16)31326-5]

89 **Oikawa K**, Ishihara R, Maeda T, Yamaguchi K, Koike A, Kawaguchi H, Tabata Y, Murotani N, Itoh H. Prognostic value of heart rate variability in patients with renal failure on hemodialysis. *Int J Cardiol* 2009; **131**: 370-377 [PMID: 18199499 DOI: 10.1016/j.ijcard.2007.10.033]

90 **Mylonopoulou M**, Tentolouris N, Antonopoulos S, Mikros S, Katsaros K, Melidonis A, Sevastos N, Katsilambros N. Heart rate variability in advanced chronic kidney disease with or without diabetes: midterm effects of the initiation of chronic haemodialysis therapy. *Nephrol Dial Transplant* 2010; **25**: 3749-3754 [PMID: 20466659 DOI: 10.1093/ndt/gfq226]

91 **Seely AJ**, Macklem PT. Complex systems and the technology of variability analysis. *Crit Care* 2004; **8**: R367-R384 [PMID: 15566580 DOI: 10.1186/cc2948]

92 **Peng CK**, Havlin S, Stanley HE, Goldberger AL. Quantification of scaling exponents and crossover phenomena in nonstationary heartbeat time series. *Chaos* 1995; **5**: 82-87 [PMID: 11538314 DOI: 10.1063/1.166141]

93 **Hu K**, Ivanov PC, Chen Z, Carpena P, Stanley HE. Effect of trends on detrended fluctuation analysis. *Phys Rev E Stat Nonlin Soft Matter Phys* 2001; **64**: 011114 [PMID: 11461232 DOI: 10.1103/PhysRevE.64.011114]

94 **Ho KK**, Moody GB, Peng CK, Mietus JE, Larson MG, Levy D, Goldberger AL. Predicting survival in heart failure case and control subjects by use of fully automated methods for deriving nonlinear and conventional indices of heart rate dynamics. *Circulation* 1997; **96**: 842-848 [PMID: 9264491 DOI: 10.1161/01.cir.96.3.842]

95 **Huikuri HV**, Mäkikallio TH, Peng CK, Goldberger AL, Hintze U, Møller M. Fractal correlation properties of R-R interval dynamics and mortality in patients with depressed left ventricular function after an acute myocardial infarction. *Circulation* 2000; **101**: 47-53 [PMID: 10618303 DOI: 10.1161/01.cir.101.1.47]

96 **Mäkikallio TH**, Huikuri HV, Mäkikallio A, Sourander LB, Mitrani RD, Castellanos A, Myerburg RJ. Prediction of sudden cardiac death by fractal analysis of heart rate variability in elderly subjects. *J Am Coll Cardiol* 2001; **37**: 1395-1402 [PMID: 11300452 DOI: 10.1016/s0735-1097(01)01171-8]

97 **Vonend O**, Rump LC, Ritz E. Sympathetic overactivity--the Cinderella of cardiovascular risk factors in dialysis patients. *Semin Dial* 2008; **21**: 326-330 [PMID: 18627567 DOI: 10.1111/j.1525-139X.2008.00456.x]

98 **Converse RL Jr**, Jacobsen TN, Toto RD, Jost CM, Cosentino F, Fouad-Tarazi F, Victor RG. Sympathetic overactivity in patients with chronic renal failure. *N Engl J Med* 1992; **327**: 1912-1918 [PMID: 1454086 DOI: 10.1056/NEJM199212313272704]

99 **Tulppo MP**, Kiviniemi AM, Hautala AJ, Kallio M, Seppänen T, Mäkikallio TH, Huikuri HV. Physiological background of the loss of fractal heart rate dynamics. *Circulation* 2005; **112**: 314-319 [PMID: 16009791 DOI: 10.1161/CIRCULATIONAHA.104.523712]

**Footnotes**

**Conflict-of-interest statement:** The authors have declared no potential conflicts of interest.

**PRISMA 2009 Checklist statement:** The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Peer-review started:** March 21, 2021

**First decision:** May 6, 2021

**Article in press:**

**Specialty type:** Urology and nephrology

**Country/Territory of origin:** United States

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B, B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Liu JM, Patel J **S-Editor:** Gao CC **L-Editor:** Filipodia **P-Editor:**

**Figure Legends**



**Figure 1 Flowchart of the literature search and study selection.** “Undesired study design” includes non-human studies (*n* = 2); “Insufficient data” includes conference abstracts that reported only area under the receiver operating characteristic curve (AUC) without 95% confidence interval (*n* = 5); “Subjects are contaminated” refers to a study that has mixed chronic kidney disease (CKD) and non-CKD subjects (*n* = 1).

****

**Figure 2 Algorithm of study population classification.** CKD: Chronic kidney disease; ESRD: End-stage renal disease; HD: Hemodialysis; *N*: Number of population classification; PD: Peritoneal dialysis.

**Table 1 Study characteristics**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Country** | **Study type** | ***n*** | **Subject** | **Age, yr** | **Male, %** | **AUC for mortality (95%CI)** | **Follow-up** |
| Dara *et al*[19], 2004 | United States | Retrospective | 476 | HD patients | 66 | 58 | APACHE III on hospital mortality 0.76 (0.66-0.84) and 30-d mortality 0.78 (0.68-0.86); SOFA score on hospital mortality 0.65 (0.55-0.75) and 30-d mortality 0.66 (0.55-0.76) | - |
| Miskulin *et al*[20], 2004 | United States | Prospective | 1779 | Outpatient dialysis patients | 62 | 53 | ICED 0.72 (0.69-0.75); CCI 0.67 (0.65-0.70); Wright- Khan indices 0.68 (0.65-0.70); Davies indices 0.68 (0.65-0.70) | 1 yr |
| Wang *et al*[21], 2007 | Hong Kong | Prospective | 238 | ESRD on continuous PD | 55.7 | 51.3 | cTnT 0.774 (0.706-0.841); High sensitivity CRP 0.691 (0.614-0.768 | 3 yr |
| Sun *et al*[22], 2008 | China | Prospective | 217 | HD patients | 65.4 | 62.2 | BNP on CV events 0.61 (0.57-0.70); NT-proBNP on CV events 0.83 (0.75-0.91) | 2 yr |
| Selim *et al*[23], 2010 | Macedonia | Prospective | 125 | HD patients | 48.8 | - | BNP > 1200 pg/mL on CV mortality 0.612 (0.473-0.750); NT-proBNP > 10000 pg/mL on CV mortality 0.747 (0.677-0.816) | 2 yr |
| Breidthardt *et al*[24], 2011 | Switzerland | Retrospective | 113 | HD patients | 67.9 | 60 | BNP: all-cause mortality 0.70 (0.60-0.81); BNP: CV mortality 0.82 (0.73-0.90) | 735 d |
| Tomaszuk-Kazberuk *et al*[25], 2011 | Poland | Prospective | 39 | HD patients | 59 | 63.8 | Perfusion defects on MCE for death 0.752 (0.582-0.878) | 3 yr |
| Chiang *et al*[26], 2016 | Taiwan | Prospective | 132 | ESRD patients on PD | 53.7 | 47.0 | Short-term detrended fluctuation analysis (DFAα1) < 0.95-0.761 (0.617-0.905) | 34 mo |
| Sato *et al*[27], 2017 | Japan | Retrospective | 302 | HD patients | 63.4 | 65.4 | Neutrophil-lymphocyte ratio for 1-yr mortality 0.791 (0.602-0.980) | 1 yr |
| Wang *et al*[28], 2018 | China | Prospective | 300 | CKD 3-5 | 60 | 53.6 | UPCR for mortality 0.78 (0.72-0.84); eGFR for mortality 0.75 (0.69-0.81); Mitral E/E’ ratio for mortality 0.74 (0.67-0.80); LV mass index for mortality 0.72 (0.65-0.79); LVEF for mortality 0.50 (0.42-0.58) | 68 mo |
| Wlazeł *et al*[29], 2018 | Poland | Prospective | 64 | HD patients | 66 | 66 |  SuPAR 0.84 (0.7-0.94) | 3 yr |
| Danial *et al*[30], 2019 | Malaysia | Retrospective | 160 | CKD 3-5 with adverse drug reaction | - | 57.5 | Mortality risk score model 0.789 (0.700-0.878) | Few weeks (until end date of ADRs) |
| Jagadeswaran *et al*[31], 2019 | India | Prospective | 129 | Pre-dialysis CKD 3-5 | 50.6 | 51.2 | Malnutrition inflammation score for mortality 0.709 (0.604-0.815) | 36 mo |
| Mukai *et al*[32], 2019 | Sweden | Prospective | 261 | CKD 5 (both dialysis and non-dialysis) | 56 | 66 | Skin autofluorescence for all-cause mortality 0.78 (0.71-0.86); Augmentation index for all-cause mortality 0.81 (0.75-0.87) | 25 mo |
| Pladys *et al*[33], 2020 | France | Retrospective | 9052 | ESRD on dialysis | 68.4 | - | Rennes score model 1(REIN and SNDS data) 0.789 (0.761–0.816); Model 2 (REIN data only) 0.794 (0.768-0.821); Wright classification 0.631 (0.621-0.639); Modified CCI 0.703 (0.689-0.716) | 1 yr |
| Shahidi *et al*[34], 2020 | Iran | Retrospective | 824 | HD patients | 57.9 | 61.8 | Hemoglobin change on mortality 0.61 (0.56-0.65) | 24.08 mo |
| Gan *et al*[35], 2021 | Australia | Prospective | 243 | CKD 3-4 | 65.6 | 62.6 | Left atrial reservoir strain for CV death 0.84 (0.76-0.90) | 3.9 yr |
| Rroji *et al*[36], 2021 | Albania | Prospective | 125 | ESRD on dialysis | 52.4 | 60.0 | CRP on CV mortality 0.80 (0.73-0.92); Left ventricular mass index on CV mortality 0.76 (0.65-0.88); Ratio of early mitral inflow velocity/annular diastolic velocity (E/E’) on CV mortality 0.75 (0.64-0.86); Systolic pulmonary artery pressure on CV mortality 0.80 (0.68-0.92); Pulse pressure on CV mortality 0.72 (0.60-0.84) | 2 yr |

APACHE: Acute physiology and chronic health evaluation; AUC: Area under receiver operating characteristic curve; BMI: Body mass index; BNP: Brain natriuretic peptide; CAPD: Continuous ambulatory peritoneal dialysis; CCI: Charlson Comorbidity Index; CKD: Chronic kidney disease; CRP: C-reactive protein; CI: Confidence interval; cTnT: Cardiac troponin T; CV: Cardiovascular; E/E’: Ratio of early inflow velocity/annular diastolic velocity; eGFR: Estimated glomerular filtration rate; ESRD: End-stage renal disease; HD: Hemodialysis; ICED: Index of coexisting disease; LV: Left ventricular; MCE: Myocardial contrast echocardiography; ND: Non-dialysis; NT-proBNP: N-terminal pro-brain natriuretic peptide; PAP: Pulmonary artery pressure; PD: Peritoneal dialysis; REIN: Renal epidemiology and information network; SOFA: Sequential organ failure assessment; SNDS: French national health insurance information system; SuPAR: Soluble urokinase plasminogen activator receptor; UPCR: Urine protein creatinine ratio.

**Table 2 Predictive factors for mortality in chronic kidney disease patients**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **AUC range** | **Interpretation** | **Predictive factors (AUC)** | **Subjects** | **Ref.** |
| ≥ 0.90 | Outstanding | - | - | - |
| 0.80-0.89 | Excellent | NT-proBNP (0.83) | HD | Sun *et al*[22] |
|  |  | BNP (0.82) | HD | Breidthardt *et al*[24] |
|  |  | SuPAR (0.84) | HD | Wlazeł *et al*[29] |
|  |  | Augmentation index (0.81) | ND, HD, PD | Mukai *et al*[32] |
|  |  | Left atrial reservoir strain (0.84) | ND | Gan *et al*[35] |
|  |  | CRP (0.80) | HD, PD | Rroji *et al*[36] |
|  |  | Systolic PAP (0.80) | HD, PD | Rroji *et al*[36] |
| 0.70-0.79 | Acceptable | APACHE III (0.76) | HD | Dara *et al*[19] |
|  |  | ICED (0.72) | HD, PD | Miskulin *et al*[20] |
|  |  | cTnT (0.77) | PD | Wang *et al*[21], |
|  |  | NT-proBNP > 10000 pg/mL (0.75) | HD | Sun *et al*[22] |
|  |  | MCE perfusion defect (0.75) | HD | Tomaszuk-Kazberuk *et al*[25] |
|  |  | DFAα1 < 0.95 (0.76) | PD | Chiang *et al*[26] |
|  |  | Neutrophil/lymphocyte ratio (0.79) | HD | Sato *et al*[27] |
|  |  | UPCR (0.78) | ND | Wang *et al*[28] |
|  |  | eGFR (0.75) | ND | Wang *et al*[28] |
|  |  | Mitral E/E’ ratio (0.74, 0.75) | ND, HD, PD | Wang *et al*[28] and Rroji *et al*[36] |
|  |  | LV mass index (0.72, 0.76) | ND, HD, PD | Wang *et al*[28] and Rroji *et al*[36] |
|  |  | Mortality risk score (0.79) | ND | Danial *et al*[30] |
|  |  | Malnutrition inflammation score (0.71) | ND | Jagadeswaran *et al*[31] |
|  |  | Skin autofluorescence (0.78) | ND, HD, PD | Mukai *et al*[32] |
|  |  | Rennes score (0.79) | HD, PD | Pladys *et al*[33] |
|  |  | Modified CCI (0.70) | HD, PD | Pladys *et al*[33] |
|  |  | Pulse pressure (0.72) | HD, PD | Rroji *et al*[36] |

APACHE: Acute physiology and chronic health evaluation; AUC: Area under receiver operating characteristic curve; BMI: Body mass index; BNP: Brain natriuretic peptide; CAPD: Continuous ambulatory peritoneal dialysis; CCI: Charlson Comorbidity Index; CKD: Chronic kidney disease; CRP: C-reactive protein; CI: Confidence interval; cTnT: Cardiac troponin T; CV: Cardiovascular; E/E’: Ratio of early inflow velocity/annular diastolic velocity; eGFR: Estimated glomerular filtration rate; ESRD: End-stage renal disease; HD: Hemodialysis; ICED: Index of coexisting disease; LV: Left ventricular; MCE: Myocardial contrast echocardiography; ND: Non-dialysis; NT-proBNP: N-terminal pro-brain natriuretic peptide; PAP: Pulmonary artery pressure; PD: Peritoneal dialysis; REIN: Renal epidemiology and information network; SOFA: Sequential organ failure assessment; SNDS: French national health insurance information system; SuPAR: Soluble urokinase plasminogen activator receptor; UPCR: Urine protein creatinine ratio.